Humulin®

The below information is provided in response to your request and may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above.

HUMULIN® (insulin human) and HUMALOG® (insulin lispro): Pharmacodynamic Properties

The pharmacodynamic properties vary among insulin products and among different individuals.

General Information for Both Human Insulin and Analog Insulin Products

  • The time course of action of any insulin may vary considerably in different individuals or at different times within the same individual (Humalog Package Insert, 2017; Humulin R U-100 Package Insert, 2015).

  • As with all insulin preparations, the duration of action of the specific insulin product is dependent on dose, site of injection, blood supply, temperature, and physical activity (Humalog Package Insert, 2017; Humulin R U-100 Package Insert, 2015).


Humalog-Specific Information

  • Products containing Humalog differ from regular human insulin because of their rapid onset of action as well as a shorter duration of activity. When used as a meal-time insulin, the dose of Humalog should be given within 15 minutes before or immediately after the meal (Humalog Package Insert, 2017).

  • Doses of the Humalog premixtures (Humalog Mix50/50 or Humalog Mix75/25) should be given within 15 minutes before a meal (Humalog Mix50/50 Package Insert, 2015; Humalog Mix75/25 Package Insert, 2015).

  • One unit of Humalog has the same glucose-lowering effect as 1 unit of regular human insulin, but its effect is more rapid and of shorter duration (Humalog Package Insert, 2017). Additional information may be found in the prescribing information for the specific Humalog product.


Pharmacodynamic Properties of Lilly Insulin Products

Table 1. Onset and Duration of Action for Lilly Insulin Products (Humalog Package Insert, 2017; Humalog Mix50/50 Package Insert, 2015; Humalog Mix75/25 Package Insert, 2015; Humulin 70/30 Package Insert, 2015; Humulin N Package Insert, 2015; Humulin R U-100 Package Insert, 2015; Humulin R U‑500 Package Insert, 2016)

Insulin Products

Onset

Duration

Humalog

More rapid onset than regular human insulin

Shorter than regular human insulin

Humulin R U-100

Approximately 30 minutes

Approximately 8 hours (range, 3 to 14 hours)

Humulin R U-500

Within 30 minutes

Up to 24 hoursa

Humalog Mix75/25b

More rapid than regular human insulin

Similar to Humulin 70/30

Humulin 70/30c

Approximately 50 minutes (range, 30 to 90 minutes)

Approximately 23 hours (range, 18 to 24 hours)

Humalog Mix50/50b

More rapid than regular human insulin

Up to 24 hours

Humulin N

Slower than regular human insulin

Longer than regular human insulin, up to 24 hours

a Credited to the high concentration of the preparation

b Humalog Mix products are a mixture of insulin lispro, a rapid-acting insulin, and insulin lispro protamine suspension, an intermediate-acting insulin.

c Humulin 70/30 is a mixture of human insulin isophane suspension, an intermediate-acting insulin, and regular human insulin, a rapid-acting insulin.



Table 2. Summary of Pharmacodynamic Properties of Insulin Products Pooled Cross‑Study Comparisona (Humalog Mix50/50 Package Insert, 2015)

Insulin Products

Dose (units/kg)

Time of Peak Activity (Hours After Dosing)b

Percent of Total Activity Occurring in the First 4 Hoursb

Humalog

0.3

2.4 (0.8-4.3)

70% (49%-89%)

Humulin R

0.32 (0.26-0.37)

4.4 (4.0-5.5)

54% (38%-65%)

Humalog Mix75/25

0.3

2.6 (1.0-6.5)

35% (21%-56%)

Humulin 70/30

0.3

4.4 (1.5-16)

32% (14%-60%)

Humalog Mix50/50

0.3

2.3 (0.8-4.8)

45% (27%-69%)

NPH

0.32 (0.27-0.40)

5.5 (3.5-9.5)

14% (3.0%-48%)

NPL componentc

0.3

5.8 (1.3-18.3)

22% (6.3%-40%)

Abbreviation: NPH = neutral protamine Hagedorn insulin

a The information supplied in this table indicates when peak insulin activity can be expected and the percent of the total insulin activity occurring during the first 4 hours. The information was derived from 3 separate glucose clamp studies in nondiabetic subjects.

b Data presented as mean (range).

c NPL component is the intermediate-acting insulin lispro protamine suspension component of Humalog Mix products.


Enclosed Prescribing Information

HUMALOG® (insulin lispro injection), for subcutaneous or intravenous use, Lilly

HUMALOG® Mix50/50 (50% insulin lispro protamine suspension and 50% insulin lispro injection [rDNA origin]), Lilly

HUMALOG® Mix75/25 (75% insulin lispro protamine suspension and 25% insulin lispro injection [rDNA origin]), Lilly

HUMULIN® 70/30 (70% human insulin isophane suspension and 30% human insulin injection [rDNA origin]), injectable suspension, for subcutaneous use, Lilly

HUMULIN® N (human insulin [rDNA origin] isophane suspension), injectable suspension, for subcutaneous use, Lilly

HUMULIN® R U-100 (regular insulin human injection [rDNA origin]), Lilly

HUMULIN® R U-500 (insulin human injection), for subcutaneous use, Lilly

References

Humalog [package insert]. Indianapolis, IN: Eli Lilly and Company; 2017.

Humalog Mix50/50 [package insert]. Indianapolis, IN: Eli Lilly and Company; 2015.

Humalog Mix75/25 [package insert]. Indianapolis, IN: Eli Lilly and Company; 2015.

Humulin 70/30 [package insert]. Indianapolis, IN: Eli Lilly and Company; 2015.

Humulin N [package insert]. Indianapolis, IN: Eli Lilly and Company; 2015.

Humulin R U-100 [package insert]. Indianapolis, IN: Eli Lilly and Company; 2015.

Humulin R U-500 [package insert]. Indianapolis, IN: Eli Lilly and Company; 2016.

Date of Last Review: March 14, 2018

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 8pm ET

Or you can

Ask us a question Chat with us

Submit a question

Visit Us @LillyMedical